Abstract LB-138: Adjuvant pembrolizumab or placebo in patients with high-risk, locally advanced cutaneous squamous cell carcinoma: Phase 3 KEYNOTE-630
Abstract Background: Local recurrence occurs within 5 years in ~20% of patients with high-risk locally advanced cutaneous squamous cell carcinoma treated with current standard-of-care surgical resection and adjuvant radiotherapy. Recent data with programmed death 1 inhibitors have demonstrated antit...
Saved in:
Published in | Cancer research (Chicago, Ill.) Vol. 80; no. 16_Supplement; p. LB-138 |
---|---|
Main Authors | , , , , , , |
Format | Journal Article |
Language | English |
Published |
15.08.2020
|
Online Access | Get full text |
Cover
Loading…
Be the first to leave a comment!